CEBPB and hepatocellular carcinoma: Recent studies reported that DNASE1L3 could inhibit glycolysis in hepatoma cells and promote the tricarboxylic acid cycle involved in PTPN2‐HK2 and CEBPβ‐p53‐PFK1 pathways, thereby inhibiting HCC progression.14, 15